Table 2: Logistic regression evaluating factors predictive of FP discussion.
| OR (95% CI) | P-values | |
| Race | ||
| Caucasian | Referent | |
| African American | 1.02 (0.68–1.54) | .908 |
| American Indian | 1.61 (0.26–9.89) | .604 |
| Asian | 0.52 (0.14–1.93) | .329 |
| Primary treatment | ||
| Surgery | Referent | |
| Chemotherapy | 1.67 (1.02–2.74) | .041 |
| Radiotherapy | 1.31 (0.82–2.11) | .261 |
| Hormonal therapy | 1.69 (0.35–8.16) | .512 |
| Received chemotherapy | ||
| No | Referent | |
| Yes | 6.99 (4.45–10.99) | < .001 |
| Site of cancer | ||
| Urothelial | Referent | |
| Prostate | 5.66 (1.68–18.66) | .005 |
| Testicular | 17.70 (4.94–63.47) | < .001 |
| Renal | 0.57 (0.13–2.49) | .455 |
| Ear/nose/throat | 0.65 (0.19–2.19) | .485 |
| Esophageal | 1.20 (0.27–5.35) | .807 |
| Gastric | 0.88 (0.20–3.92) | .869 |
| Small bowel | 1.69 (0.34–8.48) | .519 |
| Colorectal | 1.45 (0.47–4.47) | .518 |
| Hepatobiliary | 0.87 (0.24–3.18) | .835 |
| Pancreatic | 2.52 (0.79–8.07) | .12 |
| Lung | 0.57 (0.15–2.19) | .416 |
| Cardiothoracic | 0.63 (0.08–4.64) | .648 |
| Bone | 2.28 (0.47–11.16) | .308 |
| Hematologic | 1.64 (0.52–5.17) | .401 |
| Skin | 0.95 (0.22–4.09) | .942 |
| Neurologic | 2.49 (0.80–7.75) | .113 |
| Soft tissue | 1.55 (0.43–5.56) | .5 |
| Eye | 1.19 (0.16–9.05) | .865 |
| Endocrine | 0.97 (0.25–3.69) | .96 |
| Age group | ||
| 18–29 | Referent | |
| 30–39 | 0.41 (0.25–0.66) | < .001 |
| 40–49 | 0.12 (0.08–0.20) | < .001 |
| 50–60 | 0.06 (0.04–0.09) | < .001 |